KR930700103A - (+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 - Google Patents
(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올Info
- Publication number
- KR930700103A KR930700103A KR1019920703050A KR920703050A KR930700103A KR 930700103 A KR930700103 A KR 930700103A KR 1019920703050 A KR1019920703050 A KR 1019920703050A KR 920703050 A KR920703050 A KR 920703050A KR 930700103 A KR930700103 A KR 930700103A
- Authority
- KR
- South Korea
- Prior art keywords
- patient
- administering
- need
- compound according
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- (+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 및 그의 제약상 허용되는 산부가염.
- 혈전증 치료량의 제1항에 따른 화합물을 혈전중의 치료를 요하는 환자에게 투여하는 것으로 이루어지는 혈전증의 치료 방법.
- 앙기나 치료향의 제1항에 따른 화합무를 앙기나의 치료를 요하는 환자에게 투여하는 것으로 이루어진 앙기나의 치료 방법.
- 식욕 불량 치료량의 제1항에 따른 화합물을 신경성 식욕 불량의 치료를 요하는 환자에게 투여하는 것으로 이루어진 신경성 식욕 불량의 치료 방법.
- 레이노 현상을 경감 또는 완화시키기에 충분한 양의 제1항에 따른 화합물을 레이노 현상의 치료를 요하는 환자에게 투여하는 것으로 이루어진 레이노 현상의 치료 방법.
- 혈관 경련 치료량의 제1항에 따른 화합물을 관상 혈관 경련의 치료를 요하는 환자에게 투여하는 것으로 이루어진 관상 혈관 경련의 치료 방법.
- 섬유근 통증 치료량의 제1항에 따른 화합물은 섬유근 통증의 치료를 요하는 환자에게 투여하는 것으로 이루어진 섬유근 통증의 치료 방법.
- EPS 치료량의 제1항에 따른 화합물을 신경 이완 치료와 관련된 추체의 부작용의 치료를 요하는 환자에게 투여하는 것으로 이루어진 신경 이완 치료와 관련된 추체의 부작용의 치료 방법.
- 불안증 치료량의 제1항에 따른 화합물을 불안증의 치료를 요하는 환자에게 투여하는 것으로 이루어진 불안증의 경감 또는 완화 방법.
- 부정맥 치료량의 제1항에 따른 화합물을 부정맥의 치료를 요하는 환자에게 투여하는 것으로 이루어진 부정맥의 치료 방법.
- 제1항에 따른 화합물 및 불활성 담체로 이루어진 조성물.
- 제11항에 있어서, 상기 불활성 담체가 제약 담체인 조성물.
- 제11항에 있어서, 트롬복산 합성 효소 억제제를 함유하는 조성물.
- 제1항에 있어서, 따른 화합물을 환자에게 투여하는 것으로 이루어진 5HT2수용체에서의 세로토닌 작용의 길항 방법.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53195490A | 1990-06-01 | 1990-06-01 | |
US531,954 | 1990-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930700103A true KR930700103A (ko) | 1993-03-13 |
KR100211713B1 KR100211713B1 (ko) | 1999-08-02 |
Family
ID=24119769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920703050A KR100211713B1 (ko) | 1990-06-01 | 1991-04-30 | (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 |
Country Status (15)
Country | Link |
---|---|
US (6) | US5134149A (ko) |
EP (1) | EP0531410B1 (ko) |
JP (1) | JP2869512B2 (ko) |
KR (1) | KR100211713B1 (ko) |
AT (1) | ATE114467T1 (ko) |
AU (1) | AU652759B2 (ko) |
CA (1) | CA2083698C (ko) |
DE (1) | DE69105501T2 (ko) |
DK (1) | DK0531410T3 (ko) |
ES (1) | ES2067937T3 (ko) |
FI (1) | FI95370C (ko) |
GR (1) | GR3015087T3 (ko) |
HU (1) | HU213271B (ko) |
NO (1) | NO179250C (ko) |
WO (1) | WO1991018602A1 (ko) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
EP0796619A1 (en) | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
KR100258018B1 (ko) * | 1997-12-23 | 2000-07-01 | 유승필 | 티클로피딘과 은행잎 추출물을 함유한 약제조성물 |
TWI249526B (en) * | 1998-03-13 | 2006-02-21 | Aventis Pharma Inc | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US20050261341A1 (en) * | 1998-03-13 | 2005-11-24 | Aventis Pharmaceuticals Inc. | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6713627B2 (en) * | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
SE9801516D0 (sv) * | 1998-04-30 | 1998-04-30 | Maria Carlsson | M100907/4-Piperidinemethanol derivatives for autism |
GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US6277864B1 (en) | 1998-08-28 | 2001-08-21 | Aventis Pharmaceuticals Inc. | Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
HUP0202145A3 (en) * | 1998-08-28 | 2003-02-28 | Aventis Pharmaceuticals Inc Br | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
US6939879B2 (en) * | 1998-08-28 | 2005-09-06 | Aventis Pharmaceuticals Inc. | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia |
IL142479A0 (en) * | 1998-10-14 | 2002-03-10 | Aventis Pharma Inc | Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
ID28909A (id) * | 1998-12-16 | 2001-07-12 | Aventis Pharma Inc | Antagonis reseptor serotonin terenkapsulasi polimer yang dapat terurai hayati dan metode pembuatannya |
FR2787328A1 (fr) * | 1998-12-22 | 2000-06-23 | Sanofi Sa | Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures |
GB9901147D0 (en) | 1999-01-19 | 1999-03-10 | Merck Sharp & Dohme | Therapeutic agents |
US6465490B1 (en) | 1999-07-16 | 2002-10-15 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester |
ES2276688T3 (es) * | 1999-07-16 | 2007-07-01 | Aventis Pharmaceuticals Inc. | Ester mono-(3-((1-(2-(4-fluoro-fenil)-etil)-piperidin-4-il)-hidroxi-metil)-2-metoxi-fenilico) de acido sulfurico. |
DE19939756A1 (de) | 1999-08-21 | 2001-02-22 | Merck Patent Gmbh | Piperidinalkohole |
DE60013751T2 (de) * | 1999-12-29 | 2005-09-29 | Pfizer Products Inc., Groton | Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten |
RU2257384C2 (ru) * | 2000-02-29 | 2005-07-27 | Мицубиси Фарма Корпорейшн | Новые производные циклического амида |
GB0007907D0 (en) * | 2000-03-31 | 2000-05-17 | Merck Sharp & Dohme | Therapeutic agents |
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
US20030177248A1 (en) * | 2001-09-05 | 2003-09-18 | International Business Machines Corporation | Apparatus and method for providing access rights information on computer accessible content |
WO2004009586A1 (en) * | 2002-07-19 | 2004-01-29 | Biovitrum Ab | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
KR20050040921A (ko) * | 2002-08-15 | 2005-05-03 | 와이어쓰 | 체온조절 기능장애 치료를 위한 5HT2a 수용체의 항진제 |
US7345096B2 (en) | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
ES2515092T3 (es) | 2003-12-11 | 2014-10-29 | Sunovion Pharmaceuticals Inc. | Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20060069124A1 (en) * | 2004-09-07 | 2006-03-30 | Rao P S | Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases |
ES2643615T3 (es) | 2004-09-30 | 2017-11-23 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos |
WO2009152647A1 (zh) * | 2008-06-20 | 2009-12-23 | 江苏恩华药业股份有限公司 | 芳烷基哌啶衍生物及其在制备镇痛、镇静药物中的应用 |
SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833775A (en) * | 1951-08-17 | 1958-05-06 | Schering Corp | Substituted piperidines |
US3058979A (en) * | 1957-05-13 | 1962-10-16 | Smith Kline French Lab | New perfluoroalkylphenothiazine derivatives |
US3194733A (en) * | 1961-04-26 | 1965-07-13 | Olin Mathicson Chemical Corp | Phenothiazine compositions and method of treating mental disorders |
US3394131A (en) * | 1961-04-26 | 1968-07-23 | Squibb & Sons Inc | Acid esters of phenothiazine |
GB1316424A (en) * | 1969-05-20 | 1973-05-09 | Minnesota 3M Lab Ltd | Alpha-hydroxy-substituted-phenyl-alpha-2-piperidyl-methanols and process for the preparation thereof |
US3655676A (en) * | 1970-11-19 | 1972-04-11 | Smith Kline French Lab | 4-hydroxy-3-hydroxymethylphenyl-2-piperidinylcarbinols |
US4569941A (en) * | 1983-03-21 | 1986-02-11 | Usv Pharmaceutical Corp. | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal |
US4701461A (en) * | 1983-03-21 | 1987-10-20 | Usv Pharmaceutical Corporation | Substituted cyclic amines |
US4623728A (en) * | 1984-07-26 | 1986-11-18 | Pfizer Inc. | Intermediates for 1,3-disubstituted piperidine compounds as neuroleptic agents |
US4632929A (en) * | 1985-01-17 | 1986-12-30 | Usv Pharmaceutical Corp. | Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
ZA864772B (en) * | 1985-07-02 | 1987-02-25 | Merrell Dow Pharma | Novel chemical compounds |
US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
US4762842A (en) * | 1985-10-01 | 1988-08-09 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
IT1205685B (it) * | 1987-05-26 | 1989-03-31 | Erregierre Spa | Processo per la preparazione di alfa-(alchilfenil)-4-(idrossi difenilmetil)-1-piperidina butanolo |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
ZA888572B (en) * | 1987-11-23 | 1989-08-30 | Merrell Dow Pharma | Treatment of fibromyalgia |
US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
JPH02138214A (ja) * | 1987-12-10 | 1990-05-28 | Merrell Dow Pharmaceut Inc | 不安を治療する方法 |
US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
EP0325063B1 (en) * | 1988-01-21 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia |
US5064838A (en) * | 1988-01-21 | 1991-11-12 | Merrell Dow Pharmaceuticals | 1,4-disubstituted-piperidinyl compounds as pain relievers |
KR890012971A (ko) * | 1988-02-10 | 1989-09-20 | 원본미기재 | 심장혈관 항히스타민제 및 분비억제제로서의 n-치환된-아릴알킬 및 아릴알킬렌 아미노헤테로사이클릭 화합물 |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
AU629534B2 (en) * | 1988-02-24 | 1992-10-08 | A.H. Robins Company, Incorporated | New methods and related compounds |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5070087A (en) * | 1989-05-08 | 1991-12-03 | A. H. Robins Company, Incorporated | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents |
US5106855A (en) * | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
US5116846A (en) * | 1990-03-28 | 1992-05-26 | Du Pont Merck Pharmaceutical Company | N-aralkyl piperidine derivatives as psychotropic drugs |
AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
-
1991
- 1991-04-30 AU AU79509/91A patent/AU652759B2/en not_active Expired
- 1991-04-30 WO PCT/US1991/003036 patent/WO1991018602A1/en active IP Right Grant
- 1991-04-30 DK DK91910548.6T patent/DK0531410T3/da active
- 1991-04-30 AT AT91910548T patent/ATE114467T1/de not_active IP Right Cessation
- 1991-04-30 DE DE69105501T patent/DE69105501T2/de not_active Expired - Lifetime
- 1991-04-30 JP JP3510161A patent/JP2869512B2/ja not_active Expired - Lifetime
- 1991-04-30 EP EP91910548A patent/EP0531410B1/en not_active Expired - Lifetime
- 1991-04-30 HU HU9203779A patent/HU213271B/hu unknown
- 1991-04-30 CA CA002083698A patent/CA2083698C/en not_active Expired - Lifetime
- 1991-04-30 KR KR1019920703050A patent/KR100211713B1/ko not_active IP Right Cessation
- 1991-04-30 ES ES91910548T patent/ES2067937T3/es not_active Expired - Lifetime
- 1991-07-26 US US07/736,194 patent/US5134149A/en not_active Expired - Lifetime
-
1992
- 1992-11-25 FI FI925342A patent/FI95370C/fi active
- 1992-11-30 NO NO924619A patent/NO179250C/no not_active IP Right Cessation
-
1995
- 1995-01-13 US US08/372,694 patent/US5561144A/en not_active Expired - Lifetime
- 1995-02-16 GR GR950400305T patent/GR3015087T3/el unknown
- 1995-06-07 US US08/485,701 patent/US5700812A/en not_active Expired - Lifetime
- 1995-06-07 US US08/485,700 patent/US5700813A/en not_active Expired - Lifetime
- 1995-06-07 US US08/476,538 patent/US5721249A/en not_active Expired - Lifetime
-
1997
- 1997-10-02 US US08/942,629 patent/US5874445A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE114467T1 (de) | 1994-12-15 |
NO924619D0 (no) | 1992-11-30 |
AU7950991A (en) | 1991-12-31 |
JP2869512B2 (ja) | 1999-03-10 |
NO179250B (no) | 1996-05-28 |
US5874445A (en) | 1999-02-23 |
HU9203779D0 (en) | 1993-03-29 |
CA2083698A1 (en) | 1991-12-02 |
AU652759B2 (en) | 1994-09-08 |
ES2067937T3 (es) | 1995-04-01 |
WO1991018602A1 (en) | 1991-12-12 |
US5134149A (en) | 1992-07-28 |
CA2083698C (en) | 1997-11-04 |
NO179250C (no) | 1996-09-04 |
EP0531410A1 (en) | 1993-03-17 |
FI95370B (fi) | 1995-10-13 |
US5700813A (en) | 1997-12-23 |
EP0531410A4 (en) | 1993-05-26 |
FI95370C (fi) | 1996-01-25 |
GR3015087T3 (en) | 1995-05-31 |
US5700812A (en) | 1997-12-23 |
HU213271B (en) | 1997-04-28 |
US5721249A (en) | 1998-02-24 |
FI925342A0 (fi) | 1992-11-25 |
US5561144A (en) | 1996-10-01 |
DK0531410T3 (da) | 1995-01-30 |
HUT64745A (en) | 1994-02-28 |
DE69105501T2 (de) | 1995-04-13 |
EP0531410B1 (en) | 1994-11-30 |
NO924619L (no) | 1992-11-30 |
KR100211713B1 (ko) | 1999-08-02 |
DE69105501D1 (de) | 1995-01-12 |
JPH05507482A (ja) | 1993-10-28 |
FI925342A (fi) | 1992-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930700103A (ko) | (+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 | |
BR0110487A (pt) | Composição farmacêutica e método de tratamento de doenças de disfunção cognitiva em um mamìfero | |
FR2670491B1 (fr) | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. | |
EA200200111A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
DE60037836D1 (de) | ThiazoloÄ4,5-dÜpyrimidinverbindungen zur Behandlung von rheumathoider Arthritis | |
MEP36608A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
LU90098I2 (fr) | Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique | |
NO963731L (no) | Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister | |
IL128723A0 (en) | Pharmaceutical compositions containing rar antagonists and rxr agonists | |
ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
GB2285219B (en) | Use of norastemizole for the treatment of allergic disorders | |
ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
EP0337136A3 (en) | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE294572T1 (de) | Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten | |
US5854248A (en) | Nefazodone: use in migraine prophylaxis | |
KR910011787A (ko) | 항혈전성 화합물 | |
YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera | |
FR2697251B1 (fr) | N-oxydes de dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl] pipéridin-1-yl]éthanol, leur procédé de préparation et leur application en thérapeutique. | |
EA200200656A1 (ru) | НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ | |
FR2647785B1 (fr) | Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
HRP20080389A2 (en) | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | |
BRPI0016329B8 (pt) | bis-indolilmaleimidas substituídas para inibição de proliferação de células, seu processo de preparação e seu uso, bem como composição farmacêutica. | |
FR2645747B1 (fr) | Nouvelles compositions pharmaceutiques, leur procede d'obtention et leur emploi en therapeutique tumorale | |
KR880008807A (ko) | 정신병의 치료방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20100427 Year of fee payment: 12 |
|
EXPY | Expiration of term |